Cardiolink Science (Shenzhen) Medical Technology Development Co., Ltd

Cardiolink Science(Shenzhen), an innovative leader in the field of oncology intervention with its headquartered and two manufacturing facilities in China.

 

Now it has obtained 19 NMPA medical device registration certificates, make it with the most comprehensive TACE full solution platform, providing the only SS-TACE total solution in China. The product portfolios approved in overseas markets is also rapidly expanding.

Since its incorporation a decade ago by a founding team composed of clinicians and healthcare professionals, Cardiolink Science(Shenzhen) has consistently invest in R&D. The R&D team is driven by "therapy reading" and, through the “BEST” research and development system, seamlessly integrates technical engineering language with clinical needs.

Cardiolink Science(Shenzhen)'s ever-expanding product portfolio include Peripheral intervention, Coronary intervention and Neurointervention medical device, are committed to developing and producing minimally invasive intervention medical device for patients worldwide, aiming to alleviate pain and extend the lives of more patients.